Rigel Pharmaceuticals (Nasdaq: RIGL) announced plans to build a commercial organization to support the potential launch of fostamatinib, its oral ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE